
Figure 4.1: Trial Design Diagram

## **Key Eligibility Criteria**

- Locally advanced unresectable or metastatic non-squamous NSCLC
- No prior systemic treatment for advanced/metastatic NSCLC
- ECOG PS of 0 or 1
- HER2 overexpression as confirmed by central or Sponsorspecified laboratory
- PD-L1 TPS <50% as confirmed by central laboratory
- No known AGAs with locally available therapies in the first-line advanced/metastatic setting
- No known HER2 mutation



## Stratification factors:

- Prior neoadjuvant/adjuvant therapy (yes versus no)
- Smoking history (ever smoker versus never smoker)
- PD-L1 IHC expression (TPS <1% versus 1% to 49%)</li>
- HER2 IHC expression (IHC 3+ versus non-3+)

非鱗狀局部晚期無法切除或轉移性 NSCLC,未曾接受針對晚期或轉移性非鱗狀 NSCLC 的全身性抗癌治療。接受過adjuvant或neo-adjuvant治療的參與者,包括(PD-1/PD-L1)或銷類化療 的 last dose 6 個月內沒有disease progress or recurrent。